Entity

Time filter

Source Type

Scottsdale, AZ, United States

Dxl

Trademark
InNexus Biotechnology Inc. | Date: 2008-03-11

Immunological reagents for scientific and medical research use, namely, autophilic antibodies; assay kits comprising immunological reagents, namely, autophilic antibodies. Pharmaceutical, veterinary and diagnostic preparations for use in medical treatment, research and diagnosis, namely, autophilic antibodies. Medical diagnostic services and provision of medical diagnostic information based on use of autophilic antibodies in the field of diseases and conditions characterized by specific antigenic markers.


Patent
InNexus Biotechnology Inc. | Date: 2011-11-22

Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimers disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.


Bingaman M.G.,InNexus Biotechnology Inc. | Basu G.D.,InNexus Biotechnology Inc. | Golding T.C.,InNexus Biotechnology Inc. | Chong S.K.,InNexus Biotechnology Inc. | And 3 more authors.
Anti-Cancer Drugs | Year: 2010

Despite widespread use of anti-CD20 antibodies as therapeutic agents for oncologic and autoimmune indications, precise descriptions of killing mechanisms remain incomplete. Complement-dependent cytolysis and antibody-dependent cell-mediated cytotoxicity are indicated as modes of target cell depletion; however, the importance of apoptosis induction is controversial. Studies showing that the therapeutic anti-CD20 antibody rituximab (Rituxan) mediates apoptosis of tumor cell targets in vitro after cross-linking by anti-Fc reagents suggest that enhancement strategies applied to Fc-independent activities for anti-CD20 antibodies could improve therapeutic efficacy. An anti-CD20 antibody designated DXL625, with autophilic properties such as increased binding avidity, is shown here to independently induce caspase-mediated apoptosis of an established B-cell lymphoma line in vitro. Depletion of membrane cholesterol or chelation of extracellular calcium abrogated the pro-apoptotic activity of DXL625, indicating that intact lipid rafts and calcium are required for this activity. The Fc-mediated complement-dependent and antibody-dependent cellular killing mechanisms are maintained by DXL625 despite conjugation of the parental Rituxan antibody to the autophilic DXL peptide sequence. This study shows a strategy for improving anti-CD20 immunotherapy by endowing therapeutic antibodies with self-interacting properties. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source

Discover hidden collaborations